JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and increased the price target from $6 to $8.
January 24, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reaffirmed a Market Outperform rating on Benitec Biopharma and raised the price target from $6 to $8.
The increase in price target by JMP Securities suggests a positive outlook on Benitec Biopharma's stock, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100